Last reviewed · How we verify
ALBINTERFERON ALFA-2B
This drug is a long-acting interferon used with ribavirin to treat chronic hepatitis B and C.
Albumin Interferon Alfa-2b is an interferon-based therapy used in combination with ribavirin for chronic hepatitis B and C. It offers extended half-life through albumin fusion, allowing less frequent dosing.
At a glance
| Generic name | ALBINTERFERON ALFA-2B |
|---|---|
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
Albumin Interferon Alfa-2b is a modified form of interferon that helps the body's immune system fight viral infections like hepatitis B and C. The drug is designed to stay in the body longer than standard interferons by attaching to albumin, a protein that naturally circulates in the blood. This extended presence means patients may need fewer injections while still receiving effective treatment.
Approved indications
Common side effects
Key clinical trials
- A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Single Dose of Albinterferon Alfa 2b (Alb-IFN), Recombinant Human Albumin-interferon Alfa Fusi (Phase 1)
- Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC (Phase 3)
- A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection. (Phase 1)
- An Open Label Non-Randomized Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals (Phase 1)
- Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive (Phase 3)
- An Open-label, Randomized, Multicenter, Active-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of Albinterferon Alfa 2b Administered Every 4 Weeks Plus Ribavirin in Interferon Alfa- (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALBINTERFERON ALFA-2B CI brief — competitive landscape report
- ALBINTERFERON ALFA-2B updates RSS · CI watch RSS
- portfolio CI